

Angelico®

Angelico Ventures

November 2022

Ready to execute team with strong entrepreneurial & venture track record



Yves Decadt
Chairman of the Board

- Co-founder and CEO of BioLingus
- Prev. VP Business Development at SkyePharma based in Basel, Switzerland



Alex Khorokhorin
Managing Partner

- Prev. Marketing Director at Samsung Engineering and Wood Group
- Investor in Arna Genomics
- EMBA Kingston Univ, PhD World Economy



Uri Oreshin
Managing Partner

- Co-Founder of Alvansa
- Investor in CureLab Oncology & Aiternis
- HSCI Darla Moore Business School



Charlie Snedaker
Head of Origination

- Deals Origination and Leadership
- Negotiations and Business Promotion: Financial Analysis and Project Management
- Washington and Lee University



Kate Hansen
Head of Execution

- Deal Execution and Team Leadership
- Business promotion
- Copenhagen Business School, MSc/Cand.Merc



Julia Manakhova
Execution team leader

- Deal execution and team leadership (Healthcare)
- Moscow State University of Civil Aviation, Master of Economics
- Moscow State University, Neuroscience

Impactful Advisory Services for Entrepreneurs and Capital Providers

1 INDIVIDUAL APPROACH

- We help Disruptive Technology Startups bring the best Smart Money Investors and develop their value proposition to become Unicorns
- Help ensure that advances in healthcare created and shared with those who need them the most

2 READY TO EXECUTE TEAM

- Highly experienced team of IB specialists, ex-VC, Big-4 consulting, and healthcare
- Our team members created a multi-billion dollar anti-aging medicine industry
- We engaged in raising over \$465M


3 PROPRIETARY INVESTOR BASE

- Our investor base accumulated over 10+ years of continuous market presence covers all market segments and investment stages – 1,4K+ Hot Investors and 47K+ in total in the Database

4 DEEP SECTOR KNOWLEDGE

- We have a strong historic focus on and significant deal experience in healthcare, technology services
- Advisory Board of scientists support to carry out express DD of the projects

Angelico Ventures distinguishing features



Committed execution team employing active investor base tools

Support in negotiations to obtain commitments on crucial terms

Assist in the preparation of required marketing and offering materials and justify valuation

Personal manager overseeing all phases of the investment process

CREDENTIALS RECENT DEALS 2021



Angelico Ventures leadership team selected past deals



**\$6M Lead for
\$20M round**

Oncology treatment platform
technology based on cytokines



\$1,3M in SAFE

AI/ML/VP technology for
non standard speakers



CREDENTIALS HISTORICAL FOCUS



Angelico Ventures leadership team selected past deals

TRANS NOVA
INVESTMENTS

\$58M

Investment & research
collaboration agreement



UFG Private Equity

\$200M

Pharmaceutical
market consolidation

ALVANSA



JOINT-STOCK FINANCIAL CORPORATION
SISTEMA

\$200M

Equity and debt
hard investment commitment




VC MARKET HIGHLIGHTS




Ready to execute team with strong entrepreneurial & venture track record


US VC dry powder has continued to soar




While other industries are shrinking, and GDP is in decline, health is growing and increasing its share



Funding reaches \$329B in 2022 so far



Growth in combined enterprise value (2021 vs. 2016) per vertical in the MENA region (excl. Israel)



We have a large multidimensionally diversified Investor Base
1,4K+ warm Biotech/Lifesciences investors and 47K in total in the database

INVESTOR TYPES


We have successfully accumulated active involvement with all categories of VC market participants like Angels, VCs, Family Offices and Big Pharma Corporate Funds

GLOBAL COVERAGE


Our sales team has no limitations in terms of country coverage, but top priority is US, UK, Europe and Israel

TECH FOOTPRINT

Investor database is constantly updated and synced with major information providers to ensure timely and sufficient info provision



- VC Late Stage
- VC Early Stage
- Individual investors
- Private Equity
- Micro VC




- North America
- Europe
- Asia
- LatAm
- Other

SECTORAL EXPERTISE

Angelico Ventures has broad experience across multiple market segments




MEDICAL DEVICES



THERAPEUTICS




DIAGNOSTICS



ROBOTICS



DIGITAL HEALTHCARE



ALTERNATIVE CARE

AV Key Success Factors (KSF)

- Best reputation and successful track records of Company Partners and Executive Team (successfully closed deals with satisfied Clients and Investors)
- Extensive expertise in the industry and ability to attract world-leading experts to carry out technological, economical, and commercial due diligence of the Pipeline
- The largest network of targeted Smart Money Investors in Biotech/Medtech from the most active VC regions (leading VC Funds, Family Offices, Big Pharma Corporate Funds, and Business Angels networks)
- Access to the best Accelerators, University Incubators, Startup Camps, Innovative Corporations, Professional Business communities, Top Executives, and Entrepreneurs to obtain the best disruptive technology projects
- Focus on long-term relationships rather than immediate profit

AV Value Proposition

LONG

Using a credible reputation and robust industrial expertise, in parallel with a vast network of the best world Biotech/Medtech Smart Money Investors, Accelerators, and Incubators, provide affordable and effective fundraising services for the future development of potential Unicorns

SHORT

Catalyzing the development of Healthcare Unicorns

Together we bring your project to the big life

Get in touch

angelicoventures.com

✉ office@angelicoventures.com